{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"98.7","value":"50.0"},{"groupId":"OG001","lowerLimit":"15.7","upperLimit":"84.3","value":"50.0"},{"groupId":"OG002","lowerLimit":"7.5","upperLimit":"70.1","value":"33.3"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"84.2","value":"0"},{"groupId":"OG004","lowerLimit":"30.6","upperLimit":"54.6","value":"42.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"71"}],"units":"Participants"}],"description":"ORR per investigator assessment was defined as the percentage of participants whose BOR was CR or PR. The tumor response was based on GRS Olsen 2011 criteria. CR was defined as disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new sites.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with E7777 6 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG000","title":"Lead-In Part: E7777 6 mcg/kg"},{"description":"Participants were treated with E7777 9 mcg/kg by IV infusion over 60 minute on 5 consecutive days during every 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-In Part.","id":"OG001","title":"Lead-In Part: E7777 9 mcg/kg"},{"description":"Participants were treated with E7777 12 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG002","title":"Lead-In Part: E7777 12 mcg/kg"},{"description":"Participants were treated with E7777 15 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG003","title":"Lead-In Part: E7777 15 mcg/kg"},{"description":"Participants with stages I to III CTCL were treated with E7777 9 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part and in Main study part and were presented together here, as planned.","id":"OG004","title":"Main Study Part: E7777 9 mcg/kg"}],"paramType":"NUMBER","populationDescription":"Lead-in analysis set included all participants enrolled in the lead-in part and Investigator efficacy analysis set included all Stage I to III participants (both Main Study \\[n=66\\] and Lead-In \\[n=5\\]) who received study drug at 9 mcg/kg dose.","reportingStatus":"POSTED","timeFrame":"From the date of administration of the first dose of the study drug until disease progression (Up to 3 years 6 months)","title":"Lead-In Part and Main Study Part: ORR Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}